ANLOTINIB

Search structure
Status: Approved
Entry Type: Small molecule
Molecule Category: Parent
UNII: GKF8S4C432

Structure
InChI Key KSMZEXLVHXZPEF-UHFFFAOYSA-N
Smile COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
InChI
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H22FN3O3
Molecular Weight 407.45
AlogP 4.83
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 6.0
Polar Surface Area 82.39
Molecular species BASE
Aromatic Rings 4.0
Heavy Atoms 30.0

Indications

Mesh Heading Maximum Phase Reference
Lung Neoplasms Phase 1/Phase 2 ClinicalTrials
Lung Neoplasms; Small Cell Lung Carcinoma Phase 2 ClinicalTrials
Carcinoma; Carcinoma, Renal Cell Phase 2 ClinicalTrials
Histiocytoma, Malignant Fibrous; Sarcoma Phase 2 ClinicalTrials
Stomach Neoplasms Phase 2/Phase 3 ClinicalTrials
Carcinoma, Non-Small-Cell Lung Phase 4 ClinicalTrials
Lung Neoplasms; Small Cell Lung Carcinoma Phase 2 ClinicalTrials
Glioblastoma Phase 1/Phase 2 ClinicalTrials
Lung Neoplasms; Small Cell Lung Carcinoma Phase 2 ClinicalTrials
Adenocarcinoma; Adenocarcinoma of Lung Phase 2 ClinicalTrials
Carcinoma; Carcinoma, Renal Cell Phase 2 ClinicalTrials
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms Phase 2 ClinicalTrials
Intestinal Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms Phase 2 ClinicalTrials
Neoplasms Phase 1 ClinicalTrials
Leiomyosarcoma; Sarcoma; Sarcoma, Alveolar Soft Part; Sarcoma, Synovial Phase 3 ClinicalTrials
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms Phase 2/Phase 3 ClinicalTrials
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms Phase 1 ClinicalTrials
Endometrial Neoplasms; Uterine Cervical Neoplasms Phase 1/Phase 2 ClinicalTrials
Sarcoma Phase 2 ClinicalTrials
Melanoma Phase 1/Phase 2 ClinicalTrials
Bone Neoplasms Phase 2 ClinicalTrials
Thyroid Diseases; Thyroid Neoplasms Phase 2/Phase 3 ClinicalTrials
Neoplasms Phase 1 ClinicalTrials
Carcinoma, Ovarian Epithelial; Ovarian Neoplasms Phase 2 ClinicalTrials
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms Phase 3 ClinicalTrials
Carcinoma; Carcinoma, Neuroendocrine; Thyroid Diseases; Thyroid Neoplasms Phase 2/Phase 3 ClinicalTrials
Lung Neoplasms; Small Cell Lung Carcinoma Phase 2 ClinicalTrials
Sarcoma Phase 2/Phase 3 ClinicalTrials
Carcinoma; Nasopharyngeal Carcinoma Phase 2 ClinicalTrials
Carcinoma; Carcinoma, Hepatocellular Phase 2 ClinicalTrials
Lymphoma; Lymphoma, T-Cell Phase 2 ClinicalTrials
Colorectal Neoplasms Phase 2/Phase 3 ClinicalTrials
Lung Neoplasms; Small Cell Lung Carcinoma Phase 3 ClinicalTrials
Sarcoma Phase 2 ClinicalTrials
Adenocarcinoma; Neoplasms Phase 2 ClinicalTrials
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms Phase 2/Phase 3 ClinicalTrials
Carcinoma; Endometrial Neoplasms Phase 1/Phase 2 ClinicalTrials
Sarcoma; Sarcoma, Ewing Phase 1/Phase 2 ClinicalTrials
Carcinoma, Non-Small-Cell Lung Phase 4 ClinicalTrials
Cholangiocarcinoma Phase 1/Phase 2 ClinicalTrials
Neoplasms Phase 2/Phase 3 ClinicalTrials
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms Phase 2 ClinicalTrials
Carcinoma, Non-Small-Cell Lung Phase 2 ClinicalTrials
Carcinoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma Phase 2 ClinicalTrials

Related Entries

Scaffolds

Salt

Cross References

Resources Reference
CAS NUMBER 1058156-90-3
ChEMBL CHEMBL4303201
FDA SRS GKF8S4C432
Guide to Pharmacology 9601
SureChEMBL SCHEMBL2063386
ZINC ZINC000117924202
CONTENTS